Shots:

• Halozyme to receive $25M upfront plus $160 to $165M/target milestones payments based on development- regulatory & sales in addition to royalties. Roche to get rights for ENHANZE Technology for exclusive development of clinical stage candidates for therapy areas
• Roche also has an option to add two additional targets within a span of four years- in response Halozyme will receive a nomination fee for added targets. The initiation of the transaction is expected in Q4’19
• Halozyme’s ENHANZE drug discovery technology is based on recombinant human hyaluronidase enzyme (rHuPH20) with SC delivery system. In 2006- Roche & Halozyme signed an agreement for ENHANZE and developed Rituxan- Rituxan Hycela & Herceptin

  Ref: Halozyme | Image: Roche